To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: FDA Grants Atrovent Nasal Spray Pediatric Indication For Rhinorrhea URL: http://www.pslgroup.com/dg/AC2E6.htm Doctor's Guide September 1, 1998
RIDGEFIELD, CT -- Sept. 1, 1998 -- Boehringer Ingelheim Pharmaceuticals, Inc.' s Atrovent(R) (ipratropium bromide) Nasal Spray .03% for the treatment of rhinorrhea (runny nose) associated with allergic and nonallergic perennial rhinitis has now been granted and indication for use in children six years and up by the United States Food and Drug Administration. It is not indicated for the relief of nasal congestion, sneezing or postnasal drip. Atrovent Nasal Spray .03% is an anticholinergic agent that blocks the action of acetylcholine, which causes a runny nose. It provides significant relief from the first day of therapy, with no nasal rebound. In clinical trials, the most frequently reported nasal adverse events were transient episodes of epistaxis (9.0 percent versus 4.6 percent with vehicle) or nasal dryness (5.1 percent versus 0.9 percent with vehicle). The most frequently reported non-nasal adverse events were transient episodes of headache (9.8 percent versus 9.2 percent with vehicle) or upper respiratory tract infections (9.8 percent versus 7.2 percent with vehicle). Related Links: Atrovent, Boehringer Ingelheim Pharmaceuticals, Inc --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.